Methods: A total of 21 Patients with Portal hypertension from the

Methods: A total of 21 Patients with Portal hypertension from the First Affiliated Hospital of Nanchang University were exeeuted TIPS with Covered Stent in rencent 2 years and

were followed up for 4 to 14 months. The portal venous pressure pertosystemic pressure gradients, alimentary tract hemorrhage, stent reocclusion, hepatic encephalopath, blood coagulation, hepatic function, blood ammonia, iconography and endoscopy results were monitored before and after Tips treatment. Results: In all of the 21 Patients,18 cases were sueeessfully completed the operation. The rate of hemostatsis in 24 hours was 1 00%. HVPG dropped from (41.9 ± 15.9)cm H20 to (25.5 ± 13.5)cm H20, there was significant www.selleckchem.com/products/Maraviroc.html statistical signifieance. During in the 4 months–14 months of follow-up, HIF pathway The relapse rate of rehaemorrhagia was 26.7% (4/15), and occurred in 1, 2, 6, 8 month after the operation. Esophageal varices of 11 cases release, another 6 cases did not change significantly. Stent reocclusion rate 16.7% (3/18), and the total of 3 cases rehaemorrhagia. The incidence rate of hepatic encephalopathy was16.7% (3/18), symptoms of every cases disappear after symptomatic

treatment. Refractory ascites of all cases remission obviously and even disappear. The difference of hepatic function and platelet between before and after operation was not significant statistically (P > 0.05). Conclusion: The curative effect of TIPS in treating portal hypertension caused by liver cirrhosis

is exact, and is worthy of clinical application. Key Word(s): 1. TIPS; 2. Portal HyPenension; 3. Liver cirrhosis; Presenting Author: CHAO DU Additional Authors: MINGDE JIANG Corresponding Author: CHAO DU Affiliations: Chengdu Military Command Objective: Liver fibrosis is the pathological basis of chronic liver disease and it must lead to the cirrhosis. There is still no effects of drugs to reverse the liver fibrosis. In recent years medchemexpress numerous studies have confirmed that bone marrow-derived mesenchymal stem cells in the the body and outward have the potential of differentiation to liver cell, it is expected to repair or reverse the process of liver fibrosis. The genetically modified stem cells maintain the directly differentiation characteristics, while corresponding factor can improve the efficacy and is compensate for the lack of simple MSCs transplantation therapy. Matrix metalloproteinases in the liver was expressed and secreted by hepatic stellate cells (HSC) and Kupffer cell. It was zinc – calcium-dependent family of endogenous proteolytic enzymes involved in extracellular matrix degradation. It was the only enzyme that breaks down collagen fiber and almostly breaks down the ECM components outside the polysaccharide, it plays an important role in physiological and pathological processes.

Comments are closed.